Clinical trial results for
previously treated
advanced non-small cell
lung cancer (NSCLC)
For adults with previously treated advanced non-small cell lung cancer (NSCLC)
Actor portrayals.
OPDIVO is not approved for people
younger than 18 years of age.
An FDA-approved immunotherapy that was proven to increase survival for both squamous and non-squamous NSCLC compared to chemotherapy
ADVANCED NON-SQUAMOUS NSCLC
About the clinical trial
In a clinical trial of 582 people with previously treated non-squamous NSCLC that had spread or grown after treatment with platinum-based chemotherapy, 292 people were given OPDIVO and 290 people were given chemotherapy (docetaxel).
Significantly more people given OPDIVO were alive at 1 year compared to chemotherapy
People given OPDIVO lived longer compared to chemotherapy
OPDIVO
Half the people were alive
Chemotherapy (docetaxel)
Half the people were alive
In the primary analysis with a follow-up at 1 year, people given OPDIVO had a 27% lower risk of dying than those given chemotherapy.
OPDIVO will not work for everyone. Individual results may vary.
ADVANCED SQUAMOUS NSCLC
About the clinical trial
In a clinical trial of 272 people with squamous NSCLC that had spread or grown after treatment with platinum-based chemotherapy, 135 people were given OPDIVO and 137 people were given chemotherapy (docetaxel).
More people given OPDIVO were alive at 1 year compared to chemotherapy
People given OPDIVO lived longer compared to chemotherapy
OPDIVO
Half the people were alive
Chemotherapy (docetaxel)
Half the people were alive
In the primary analysis with a follow-up at 1 year, people given OPDIVO had a 41% lower risk of dying than those given chemotherapy.
OPDIVO will not work for everyone. Individual results may vary.
“Both my wife and I cried. I can tell you one thing, that having cancer made me take another look at golf.”
John’s story
John’s story
John is a husband, father of two, and a passionate golfer. Learn more about his experience with OPDIVO for his previously treated NSCLC.
Getting an infusion
See your recommended treatment plan and what to expect from an infusion
For adults with previously treated advanced non-small cell lung cancer
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.